Abstracts tagged "remission"

Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Josef Smolen¹, Yihan Li², Iain Sainsbury², Stefan Florentinus², Kershnie Rambalee² and GR Burmester³, ¹Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting
Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam², Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…
Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Francesca Ometto¹, Bernd Raffeiner^2,3, Costantino Botsios², Davide Astorri⁴, Lara Friso², Livio Bernardi⁵, Leonardo Punzi⁶ and Andrea Doria², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, ⁴Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, ⁵Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ⁶Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Melanie Hagen¹, Camille P Figueiredo², Jayme Fogagnolo Cobra³, Judith Haschka⁴, Michaela Reiser⁵, Matthias Englbrecht⁶, Axel J. Hueber⁷, Bernhard Manger⁶, Arnd Kleyer⁸, Stephanie Finzel⁹, Hans-Peter Tony¹⁰, Stefan Kleinert¹¹, Joerg Wendler¹², Florian Schuch¹², Monika Ronneberger¹², Martin Feuchtenberger¹³, Martin Fleck¹⁴, Karin Manger¹⁵, Wolfgang Ochs¹⁶, Matthias Schmitt-Haendle¹⁷, H.-M. Lorenz¹⁸, HG Nüßlein¹⁹, R Alten²⁰, Joerg C. Henes²¹, Klaus Krüger²², Georg Schett⁷ and Juergen Rech⁷, ¹Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ³Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ⁴Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁹Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ¹⁰Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹²Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁴Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁵Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁶Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ¹⁷Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁸Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, ¹⁹University of Erlangen, Nürnberg, Germany, ²⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ²¹Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²²Praxiszentrum St. Bonifatius, München, Germany
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
Abstract Number: 132 • 2016 ACR/ARHP Annual Meeting
Ultrasound Performed Among RA Patients in Real Life Setting Can Predict Loss of Remission, Especially When Done Early after Reaching Remission
Pascal Zufferey¹, Giorgio Tamborrini², Burkhard Moeller³, Adrian Ciurea⁴, Laure Brulhart⁵, Sandra Blumhardt⁶, Martin Toniolo⁷ and Hans Ruedi Ziswiler⁸, ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²Bethesda spital, Basel, Switzerland, ³Rheumatology & Clin Immunology, Inselspital Bern, Bern, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ⁵médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁸Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as long…
Abstract Number: 133 • 2016 ACR/ARHP Annual Meeting
Agreement Between DAS28-ESR, DAS28-CRP, SDAI, CDAI (Simplified/Clinical Disease Activity Index), ACR/EULAR Remission Criteria and Ultrasound Scoring (Naredo-12) in Patients with Rheumatoid Arthritis in Routine Care
Marion Cugnet¹, Mélanie Trabelsi², Paul Ornetti¹, Philippe Gaudin³, Stéphanie Rouanet⁴ and Athan Baillet², ¹Rheumatology, Dijon University Hospital, France, Dijon, France, ²Rheumatology, Grenoble University Hospital, France, Echirolles, France, ³Grenoble University Hospital, France, Grenoble, France, ⁴StatEthic, Levallois-Perret, France, Levallois Perret, France
Background/Purpose: Clinical remission is now a realistic goal in managing rheumatoid arthritis (RA) with treat to target strategy assessed according to different composite scores (DAS28,…
Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Stefano Alivernini¹, Luca Petricca¹, Laura Bui², Barbara Tolusso¹, Gabriele Di Sante¹, Roberta Benvenuto², Anna Laura Fedele¹, Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…
Abstract Number: 546 • 2016 ACR/ARHP Annual Meeting
Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Gulsen Ozen¹, Ali Ugur Unal², Haner Direskeneli³ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Patient global assessment (PtGA), despite not being exclusively related to disease activity, is included in Boolean-based remission (BR) criteria for RA. This study evaluated…
Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Julio Ramírez¹, Andrea Cuervo², Jose Antonio Narváez³, Virginia Ruiz-Esquide², Javier Hernández-Gañán³, Raquel Celis⁴, Jose Inciarte-Mundo², M. Victoria Hernández², Jose L. Pablos⁵, Raimon Sanmarti² and Juan D. Cañete², ¹Rheumatology, Hospital Clínic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Radiology, Hospital Bellvitge, Barcelona, Spain, ⁴Rheumatology, Arthritis Unit, Barcelona, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…
Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José Miguel Senabre-Gallego¹, José Rosas¹, Francisca Llinares-Tello², Mariana Marco-Mingot², Ana Pons¹, Xavier Barber³, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Marisa Lorente⁴, Marina Sanchís³, Juan Molina², Mario García-Carrasco⁵ and AIRE-MB, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³CIO, Universidad Miguel Hernández, Elche, Spain, ⁴Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…
Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting
Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study
Renaud DESBARBIEUX, 59037, CHRU de Lille, Lille, France
Background/Purpose: The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 1319 • 2015 ACR/ARHP Annual Meeting
18F-Fluorodeoxyglucose Positron Emission Computer Tomography and Ultrasonography for Assessing Remission in Patients with Rheumatoid Arthritis
Charline Rinkin¹, Pacôme Fosse², Nathalie Chapelier¹, Laurence Seidel³, Adelin Albert³, Roland Hustinx⁴ and Michel Malaise¹, ¹Rheumatology Department, CHU of Liège, Liège, Belgium, ²Nuclear Medicine Department, CHU of Angers, Angers, France, ³Biostatistic Department, CHU of Liège, Liège, Belgium, ⁴Nuclear Medicine Department, CHU of Liège, Liège, Belgium
Background/Purpose: The disease activity score based on 28 joints (DAS-28) might not be sufficient to assess remission in rheumatoid arthritis (RA). Several studies have shown…
Abstract Number: 2591 • 2015 ACR/ARHP Annual Meeting
Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Pascal Zufferey¹, Myriam Riek², Giorgio Tamborrini³, Laure Brulhart⁴, Martin Toniolo⁵, Sandra Blumhardt⁶, Burkhard Moeller^7,8 and Hans Ruedi Ziswiler⁹, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³Rheumatologie, Bethesda spital, Basel, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁸Rheumatology, Inselspital University Hospital, Bern, Switzerland, ⁹Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].